Prostatic artery embolization in treatment of benign prostatic hyperplasia: outcome and efficacy in medium-sized compared to large prostates
Abstract
Prostate artery embolization (PAE) is a minimally invasive procedure commonly performed to treat lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia. International Prostate Symptom Score (IPSS) is a validated patient questionnaire quantifying LUTS, and quality of life (QOL) and postvoiding residual volume (PVR) were used for patient selection for PAE. Prostate volume is an easily estimated objective parameter across multiple imaging modalities specially with ultrasound. We are comparing the result of embolization by comparing it in large (over 80 mL) and medium-sized prostates (from 51 to 80 mL) volume. We looked at a sample of 88 cases performed at a large teaching hospital between January 2022 and August 2024 with 6-month follow-up. Embospheres between 300/500 microns were injected into the prostatic arteries bilaterally (if technically feasible). Ultrasound was used to measure to estimate prostatic volume. N = 42 had an estimated volume (range 51–80 mL) and N = 46 had an estimate volume > 80 mL. IPSS, QOL, PVR and PV were assessed before and at 1-, 3- and 6-months post-procedure which were collected. The aim of this study is to compare efficacy and outcome of PAE in medium-sized prostate in comparison with the large prostates. Both medium-sized and large prostate groups showed statistically significant reductions in prostate volume, IPSS, QoL, and PVR over time (P-value < 0.001). However, while the percentage reduction in prostate volume was…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.